Mendoza Fabian, Derk Chris T
Division of Rheumatology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107-5541, USA.
J Clin Rheumatol. 2007 Aug;13(4):187-92. doi: 10.1097/RHU.0b013e318124a89e.
To describe the systemic sclerosis mortality rates in the United States between 1999 and 2002, a time period in which a new coding system was used to record deaths, and to describe its implications in patient care.
We used the mortality database from the National Center of Health Statistics and with the use of ICD-10 codes for systemic sclerosis calculated death rates by gender, race, age, state, and region for the United States. Death rates are expressed as per million population.
Age-adjusted death rates for systemic sclerosis were 6.8 cases per million in women, 2.1 cases per million in men, and 4.7 cases per million for the whole population. Death rates peaked a decade earlier in the African American population when compared with those in the white population (65-74 vs. 75-84 years of age). Age-adjusted mortality was highest in African American women at 9.5 cases per million.
Mortality rates for systemic sclerosis are slightly higher since the implementation of the new disease-specific ICD-10 coding system for recording deaths. Death rates related to systemic sclerosis among the African American population are remarkably higher than those among the white population; this is believed to be related to the more aggressive disease seen in the African American patients and to the disparity of healthcare resources. These findings suggest that earlier and more aggressive treatment is warranted in the African American population, with more frequent follow-up and preventive care.
描述1999年至2002年美国系统性硬化症的死亡率,这一时期使用了新的编码系统记录死亡情况,并描述其对患者护理的影响。
我们使用了国家卫生统计中心的死亡率数据库,通过国际疾病分类第十版(ICD - 10)中系统性硬化症的编码,计算了美国按性别、种族、年龄、州和地区划分的死亡率。死亡率以每百万人口表示。
系统性硬化症的年龄调整死亡率女性为每百万6.8例,男性为每百万2.1例,总体为每百万4.7例。与白人相比,非裔美国人的死亡率在十年前达到峰值(65 - 74岁与75 - 84岁)。年龄调整后的死亡率在非裔美国女性中最高,为每百万9.5例。
自实施用于记录死亡的新的特定疾病ICD - 10编码系统以来,系统性硬化症的死亡率略有上升。非裔美国人中与系统性硬化症相关的死亡率显著高于白人;这被认为与非裔美国患者中更具侵袭性的疾病以及医疗资源的差异有关。这些发现表明,对于非裔美国人,有必要进行更早、更积极的治疗,并增加随访和预防性护理的频率。